Catalyst Pharmaceuticals
Healthcare · Biotech
Angelini Pharma to buy Catalyst Pharmaceuticals in $4.1B all‑cash deal
May 7, 2026$4.1B
Angelini Pharma will acquire Catalyst Pharmaceuticals for $4.1B in cash at $31.50 per share, a 21% premium, in a merger expected to close in Q3 2026.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.